Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Pliant Therapeutics (PLRX) Invested Capital (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Invested Capital for 7 consecutive years, with $181.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Invested Capital fell 45.79% to $181.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $181.2 million, a 45.79% decrease, with the full-year FY2025 number at $181.2 million, down 45.79% from a year prior.
  • Invested Capital was $181.2 million for Q4 2025 at Pliant Therapeutics, down from $230.7 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $571.9 million in Q1 2023 to a low of $157.7 million in Q2 2022.
  • A 5-year average of $329.6 million and a median of $305.4 million in 2022 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: skyrocketed 507.98% in 2021, then crashed 45.79% in 2025.
  • Pliant Therapeutics' Invested Capital stood at $199.1 million in 2021, then soared by 62.4% to $323.3 million in 2022, then skyrocketed by 49.61% to $483.6 million in 2023, then plummeted by 30.88% to $334.3 million in 2024, then plummeted by 45.79% to $181.2 million in 2025.
  • Per Business Quant, the three most recent readings for PLRX's Invested Capital are $181.2 million (Q4 2025), $230.7 million (Q3 2025), and $250.4 million (Q2 2025).